Related Experiment Video

Updated: Jul 5, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Clinical biomarkers of kinase activity: examples from EGFR inhibition trials

Mechthild Krause1, Michael Baumann

  • 1Department of Radiation Oncology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany. mechthild.krause@tu-dresden.de

Cancer Metastasis Reviews
|April 23, 2008
PubMed
Abstract

Insights

Predicting patient response to epidermal growth factor receptor (EGFR) inhibitors is crucial for personalized cancer therapy. Biomarkers are needed to guide treatment, especially in radiation oncology where they may differ from chemotherapy regimens.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Patient response to epidermal growth factor receptor (EGFR) inhibitors varies significantly.
  • This variability exists across different inhibitors, combination schedules, and individual patients.

Purpose of the Study:

  • To review current predictors for EGFR inhibitor efficacy.
  • To explore biomarkers for EGFR inhibitors used alone or with chemotherapy.

Main Methods:

  • Literature review of existing studies on EGFR inhibitors and predictive biomarkers.
  • Analysis of preclinical radiotherapy data.

Main Results:

  • Current predictors for EGFR inhibitors in monotherapy and combination chemotherapy are summarized.
  • Candidate biomarkers for radiation oncology are identified.

Conclusions:

  • Biomarker development is essential for individualizing cancer therapy.
  • Biomarkers for EGFR inhibitors in radiation oncology require separate validation due to unique interactions with irradiation.

More Related Videos

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...